Over 1,000 patients with chronic granulocytic leukemia (CGL) have been given allogeneic bone marrow transplantation (BMT) in less than 10 years (Fefer, 1979, worldwide 1986), of which 455 by the IBMTR, 672 by the EBMT (with some overlap with the former) and 198 from Seattle, and some firm conclusions have been reached, while other aspects remain or have become controversial. It is now firmly established that younger patients in chronic phase (CP) do better than older ones, although the upper age limit is not defined. The hope that BMT could be successfully performed in the accelerated phase, thus allowing the postponement of a potentially hazardous procedure until it becomes unescapable, has been shown to be fallacious. Indeed, a significant difference in survival according to whether BMT was performed ‘early’ or ‘late’ in CP has been found in Seattle, but not confirmed by the IBMTR report. The treatment of the spleen (splenectomy, radiation, none) was found not to influence the outcome by the EBMT, but the same group is conducting a second, more extensive randomized study. Depletion of postthymic T lymphocytes is an efficient procedure to reduce graft-versus-host disease, and thus to facilitate non-HLA identical BMT, but the significant and distressing augmentation of relapses, both cytogenetic and clinical, reported by the majority of the clinical studies cast grave doubts on its utility, at least in its present form

Keywords:
Chronic granulocytic leukemia, Ph1 chromosome, Graft-versus-host disease
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.